Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 17,016 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Elevate Clear all
Completed Phase 2 Interventional Results available

Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis

NCT00094172
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 30, 2026, 8:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Hyaluronic Acid vs Platelet Rich Plasma: Effects on Clinical Outcomes and Intra-articular Biology for the Treatment of Knee Osteoarthritis

NCT02588872
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Platelet-rich Plasma (PRP), Hyaluronic Acid
Biological
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 30, 2026, 8:30 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Speech Perception and High Cognitive Demand

NCT04997577
View directory record Official record
Conditions
Speech Intelligibility, Aging
Interventions
Auditory-cognitive training paradigm, Auditory training paradigm
Behavioral
Lead sponsor
University of Maryland, College Park
Other
Eligibility
65 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
2
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 30, 2026, 8:30 PM EDT
Completed Phase 2 Interventional Results available

Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV

NCT01205581
View directory record Official record
Conditions
HIV, Cancer
Interventions
Fluzone High Dose Vaccine, Fluzone Standard Dose Vaccine
Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
3 Years to 21 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 30, 2026, 8:30 PM EDT
Completed Not applicable Interventional

High-Flow Oxygen Therapy Following Tracheostomy

NCT03721419
View directory record Official record
Conditions
Acute Respiratory Failure
Interventions
High Flow High Humidity device, Low Flow High Humidity device
Device
Lead sponsor
Barnes-Jewish Hospital
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 30, 2026, 8:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.

NCT00784719
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
CP-690,550, Cyclosporine, CP-690,550 Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
27
States / cities
Chandler, Arizona • Peoria, Arizona • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Oct 30, 2026, 8:30 PM EDT
Not yet recruiting Phase 2 Interventional

Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study

NCT07662928
View directory record Official record
Conditions
Adult Burkitt Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin, Echocardiography Test, Epcoritamab, Etoposide, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography, Prednisone, Rituximab, Vincristine
Procedure · Drug · Biological
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 8:30 PM EDT
Completed Not applicable Interventional

Targeted Lifestyle Change Group Prenatal Care

NCT04090307
View directory record Official record
Conditions
Pregnancy, Gestational Diabetes
Interventions
TLC Group Prenatal Care
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
13 Years and older · Female only
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
St Louis, Missouri • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 30, 2026, 8:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effect Study of AG120 in Healthy Subjects

NCT02579707
View directory record Official record
Conditions
Healthy
Interventions
AG120
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 30, 2026, 8:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Primary Prevention Youth Suicide Trial in Colorado High Schools Prevention Among Colorado High School Students

NCT03014271
View directory record Official record
Conditions
Suicide, Sexual Violence
Interventions
Sources of Strength (SOS) Prevention Program
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
13 Years to 19 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 30, 2026, 8:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical Practice

NCT04241796
View directory record Official record
Conditions
Cancer
Interventions
Multi-Cancer Early Detection Test
Device
Lead sponsor
GRAIL, Inc.
Industry
Eligibility
50 Years and older
Enrollment
6,662 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
11
States / cities
Roseville, California • Pensacola, Florida • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 30, 2026, 8:30 PM EDT
Completed Phase 3 Interventional

A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol

NCT00138762
View directory record Official record
Conditions
Hyperlipidemia
Interventions
torcetrapib/atorvastatin, atorvastatin, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
3,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
96
States / cities
Mobile, Alabama • Mesa, Arizona • Oro Valley, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 30, 2026, 8:30 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

NCT04989946
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix, pTVG-AR, Nivolumab, Cemiplimab, Fianlimab, FLT PET/CT
Drug · Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 30, 2026, 8:30 PM EDT
Terminated Early Phase 1 Interventional

124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study

NCT01583842
View directory record Official record
Conditions
Neuroblastoma
Interventions
124I-Metaiodobenzylguanidine (MIBG) (no-carrier added), 124I-MIBG (carrier added), Positron Emission Tomography (PET) /Computerized tomography (CT)
Drug · Procedure
Lead sponsor
Miguel Pampaloni
Other
Eligibility
3 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 30, 2026, 8:30 PM EDT
Recruiting Not applicable Interventional

Development of a Personalized, Psychosocial Intervention for Menopausal Individuals With Elevated Dementia Risk

NCT06965686
View directory record Official record
Conditions
Menopausal, Dementia
Interventions
PERI-MIND
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
40 Years to 58 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 30, 2026, 8:30 PM EDT
Terminated Phase 4 Interventional Results available

A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)

NCT03859869
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency (EPI)
Interventions
Pancrelipase, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
21 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 30, 2026, 8:30 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors

NCT00470366
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
Interventions
pegfilgrastim, cisplatin, ifosfamide, paclitaxel
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Oct 30, 2026, 8:30 PM EDT
Completed No phase listed Observational

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study

NCT03911466
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome, Drug Abuse in Pregnancy
Interventions
Buprenorphine Injection, Buprenorphine Sublingual Product
Drug
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
12
States / cities
Jacksonville, Florida • Boston, Massachusetts • Albuquerque, New Mexico + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 30, 2026, 8:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects

NCT02135302
View directory record Official record
Conditions
Impaired Hepatic Function
Interventions
eravacycline
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
3
States / cities
Lakewood, Colorado • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 30, 2026, 8:30 PM EDT
Completed Not applicable Interventional Results available

Comparative Effects of Nebivolol and Metoprolol on Female Sexual Function

NCT00995072
View directory record Official record
Conditions
Hypertension, Female Sexual Dysfunction
Interventions
nebivolol and metoprolol succinate, metoprolol succinate and nebivolol
Drug
Lead sponsor
East Coast Institute for Research
Network
Eligibility
40 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 30, 2026, 8:30 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder

NCT06115603
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Cannabigerol, Placebo
Drug · Other
Lead sponsor
University of Arkansas, Fayetteville
Other
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 30, 2026, 8:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Translating Habituation Research to Interventions for Pediatric Obesity

NCT01208870
View directory record Official record
Conditions
Pediatric Obesity, Habituation
Interventions
Variety Group, Nutrition Education Control
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
8 Years to 12 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 30, 2026, 8:30 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors

NCT02110069
View directory record Official record
Conditions
Kaposiform Hemangioendothelioma (KHE), Kasabach-Merritt Syndrome, Tufted Angioma
Interventions
Vincristine, Sirolimus
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 31 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
7
States / cities
Palo Alto, California • Atlanta, Georgia • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 30, 2026, 8:30 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM)

NCT01769456
View directory record Official record
Conditions
HIV Infection
Interventions
PCC, Emtricitabine/tenofovir (FTC/TDF (Truvada®))
Behavioral · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years to 17 Years · Male only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 30, 2026, 8:30 PM EDT